Bellevue Group’s Cellectis CLLS Stock Holding History

Bellevue Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-82,500	Closed	-$670K	–	180
2021 Q4	$670K	Hold	82,500	–	–	0.01%	157
2021 Q3	$1.04M	Sell	82,500 -1,000	-1%	-$13.9K	0.01%	157
2021 Q2	$1.29M	Hold	83,500	–	–	0.01%	147
2021 Q1	$1.69M	Hold	83,500	–	–	0.02%	146
2020 Q4	$2.26M	Hold	83,500	–	–	0.03%	144
2020 Q3	$1.54M	Hold	83,500	–	–	0.02%	148
2020 Q2	$1.49M	Buy	83,500 +8,200	+11%	+$125K	0.02%	141
2020 Q1	$693K	Buy	+75,300	New	+$1.12M	0.01%	148
2019 Q1	–	Sell	-46,750	Closed	-$778K	–	140
2018 Q4	$778K	Sell	46,750 -2,850	-6%	-$66.1K	0.05%	123
2018 Q3	$1.4M	Sell	49,600 -1,000	-2%	-$28.7K	0.09%	116
2018 Q2	$1.43M	Sell	50,600 -1,500	-3%	-$44.7K	0.12%	103
2018 Q1	$1.64M	Buy	52,100 +27,750	+114%	+$877K	0.16%	90
2017 Q4	$710K	Buy	+24,350	New	+$663K	0.07%	116

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group's CLLS Position: Q1 2022 in Review

Bellevue Group sold out of Cellectis (CLLS) in Q1 2022, closing a stake of 82,500 shares — an estimated $670K sold.

Bellevue Group first reported a position in CLLS in Q4 2017 and held it in 13 quarters. The position peaked at $2.26M in Q4 2020. 51 funds tracked by Wall St. Rank hold CLLS as of Q1 2022.

Bellevue Group reported no remaining Cellectis position as of Q1 2022 after selling out during the quarter.
Bellevue Group sold 82,500 Cellectis shares in Q1 2022, an estimated $670K.
Bellevue Group first reported a position in Cellectis in Q4 2017 and held it in 13 quarters.
Bellevue Group's Cellectis position peaked at $2.26M in Q4 2020.
51 funds tracked by Wall St. Rank held Cellectis as of Q1 2022.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.